Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiviral Resistance Analysis Requested In FDA Draft Guidance

Executive Summary

An analysis of resistance activity associated with antiviral drugs should be conducted prior to the initiation of clinical studies, FDA recommends in a draft guidance released May 25

You may also be interested in...



HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing

A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version

HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing

A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version

Antibacterial Pipeline Hampered By Emerging Resistance From Pharma

Pharma companies may need to place increased emphasis on discovery and development of novel anti-infective agents in order to address the proliferation of multidrug-resistant gram-negative infections

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel